

BioGaia®

Press Release 3rd of June 2010

BioGaia signs agreement for China

The agreement gives the pharmaceutical biotechnology company Asia United (China) Medical Co. Limited the exclusive rights to sell BioGaia's probiotic drops in Mainland China.

– This is a firm first step into the Chinese market for our branded supplement products, says Peter Rothschild, President, BioGaia AB.

Launch of the product is estimated at the end of 2011 following relevant local registration which will be taken care of by Asia United. The products will be sold under the BioGaia brand. About 40 % of BioGaia's sales of finished products are today sold under the BioGaia brand or are co-branded.

Asia United is a member of the Unilab Group, a privately held regional pharmaceutical and healthcare company with a leading position in Southeast Asia and with strong brands in the Philippines, Indonesia, Thailand, Malaysia, Singapore, Vietnam and Myanmar.

Asia United primarily sells oral cholera vaccines and growth hormones. Through 27 regional offices it covers the entire country with over 300 medical sales representatives visiting paediatricians and travel clinics. With its vast experience of marketing and distribution of cold-chain pharmaceutical products, Asia United is ideally suited to handle BioGaia's probiotic drops, as they require refrigeration.



– We are very pleased to add this product to our growing business in China and see great potential for this well-documented and innovative product in a growing Chinese probiotics market, says Dr Lee, Director, Asia United.

– This is an important first step for us in to China and we are convinced that Asia United is an ideal partner to help us establish our drops in a very large and growing market, says Peter Rothschild, President, BioGaia AB.

For additional information contact:

Dr Lee, Director, Asia United, telephone +86 (21) 50 31 88 00
Peter Rothschild, President, telephone: +46 8 -555 293 00

Latest press releases from BioGaia:

2010-05-26	Change in number of shares in BioGaia AB
2010-05-10	New study published: <i>Lactobacillus reuteri</i> Protectis reduced gastrointestinal symptoms and hospital stay in premature newborns
2010-05-07	Annual General Meeting of BioGaia

BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium *Lactobacillus reuteri* (Reuteri), which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm.
www.biogaia.com